Literature DB >> 1683835

Pharmacokinetics of intravenous bisoprolol in obese and non-obese volunteers.

C Le Jeunne1, J M Poirier, G Cheymol, O Ertzbischoff, F Engel, F C Hugues.   

Abstract

The pharmacokinetics of a single i.v. dose of dl-bisoprolol 0.16 mg.kg-1 ideal body weight has been studied in 8 obese women (mean weight 91 kg; 161% of ideal body weight) and 8 non-obese women (51 kg; 94% of ideal body weight). Compared to the controls, the obese subjects showed an increase in the total apparent volume of distribution (Vz) (182 vs 1351) and a decrease in Vz per kg body weight (2 vs 2.71.kg-1). There was a negative correlation between Vz l.kg-1 and the percentage of ideal body weight (r = -0.672). Total body clearance was increased, but t1/2 and renal clearance was unchanged. It is concluded that tissue diffusion of bisoprolol in obese subjects is limited, despite its lipophilicity, possibly because of alteration in the blood flow to adipose tissue produced by bisoprolol.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1683835     DOI: 10.1007/BF00265912

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  18 in total

1.  A comparison of the pharmacokinetics of propranolol in obese and normal volunteers.

Authors:  S L Bowman; S A Hudson; G Simpson; J F Munro; J A Clements
Journal:  Br J Clin Pharmacol       Date:  1986-05       Impact factor: 4.335

2.  An investigation of the comparative liposolubilities of beta-adrenoceptor blocking agents.

Authors:  P B Woods; M L Robinson
Journal:  J Pharm Pharmacol       Date:  1981-03       Impact factor: 3.765

3.  Rapid and sensitive high-performance liquid chromatographic determination of bisoprolol in plasma and urine.

Authors:  J M Poirier; M Perez; G Cheymol; P Jaillon
Journal:  J Chromatogr       Date:  1988-04-29

4.  Basic pharmacokinetics of bisoprolol, a new highly beta 1-selective adrenoceptor antagonist.

Authors:  G Leopold; J Pabst; W Ungethüm; K U Bühring
Journal:  J Clin Pharmacol       Date:  1986 Nov-Dec       Impact factor: 3.126

5.  Alterations in drug distribution and clearance due to obesity.

Authors:  D R Abernethy; D J Greenblatt; M Divoll; J S Harmatz; R I Shader
Journal:  J Pharmacol Exp Ther       Date:  1981-06       Impact factor: 4.030

Review 6.  Drug disposition in obese humans. An update.

Authors:  D R Abernethy; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

7.  Digoxin disposition in obesity: clinical pharmacokinetic investigation.

Authors:  D R Abernethy; D J Greenblatt; T W Smith
Journal:  Am Heart J       Date:  1981-10       Impact factor: 4.749

8.  Comparative pharmacokinetics of intravenous propranolol in obese and normal volunteers.

Authors:  G Cheymol; J M Poirier; J Barre; A Pradalier; J Dry
Journal:  J Clin Pharmacol       Date:  1987-11       Impact factor: 3.126

9.  Disparate cardiovascular effects of obesity and arterial hypertension.

Authors:  F H Messerli; K Sundgaard-Riise; E Reisin; G Dreslinski; F G Dunn; E Frohlich
Journal:  Am J Med       Date:  1983-05       Impact factor: 4.965

10.  Double-blind comparison of the beta 1-selectivity of single doses of bisoprolol and atenolol.

Authors:  P C Chang; S van Veen; P Vermeij; P van Brummelen
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

View more
  8 in total

Review 1.  Effects of obesity on pharmacokinetics implications for drug therapy.

Authors:  G Cheymol
Journal:  Clin Pharmacokinet       Date:  2000-09       Impact factor: 6.447

Review 2.  Impact of obesity on drug metabolism and elimination in adults and children.

Authors:  Margreke J E Brill; Jeroen Diepstraten; Anne van Rongen; Simone van Kralingen; John N van den Anker; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2012-05-01       Impact factor: 6.447

Review 3.  What is the best size descriptor to use for pharmacokinetic studies in the obese?

Authors:  Bruce Green; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

Review 4.  Clinical pharmacokinetics of drugs in obesity. An update.

Authors:  G Cheymol
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

5.  Bisoprolol pharmacokinetics and body composition in patients with chronic heart failure: a longitudinal study.

Authors:  Katja Cvan Trobec; Iztok Grabnar; Mojca Kerec Kos; Tomaz Vovk; Jurij Trontelj; Stefan D Anker; Giuseppe Rosano; Mitja Lainscak
Journal:  Eur J Clin Pharmacol       Date:  2016-03-21       Impact factor: 2.953

6.  Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling.

Authors:  Guo-fu Li; Kun Wang; Rui Chen; Hao-ru Zhao; Jin Yang; Qing-shan Zheng
Journal:  Acta Pharmacol Sin       Date:  2012-10-22       Impact factor: 6.150

Review 7.  The effect of obesity, macronutrients, fasting and nutritional status on drug-metabolizing cytochrome P450s: a systematic review of current evidence on human studies.

Authors:  Meysam Zarezadeh; Ahmad Saedisomeolia; Mahoor Shekarabi; Masoud Khorshidi; Mohammad Reza Emami; Daniel J Müller
Journal:  Eur J Nutr       Date:  2020-11-03       Impact factor: 5.614

8.  Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup.

Authors:  Josée Bouchard; Greene Shepherd; Robert S Hoffman; Sophie Gosselin; Darren M Roberts; Yi Li; Thomas D Nolin; Valéry Lavergne; Marc Ghannoum
Journal:  Crit Care       Date:  2021-06-10       Impact factor: 9.097

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.